HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial

Condition studied

Cytomegalovirus infection in solid-organ transplant recipients.

Investigational medicinal product(s)

Eligibility

Primary endpoint

Change in CMV Viral Load (log10 IU/mL) from Baseline to Week 3.

Endpoint detail

Change in the CMV-specific Immune Signature., Ability of baseline immune signature to stratify patients.